Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock, par value $0.00001 per share
-
Shares outstanding
-
108M
-
Number of holders
-
109
-
Total 13F shares, excl. options
-
63.2M
-
Shares change
-
+4.08M
-
Total reported value, excl. options
-
$883M
-
Value change
-
+$55.6M
-
Put/Call ratio
-
1.1
-
Number of buys
-
57
-
Number of sells
-
-33
-
Price
-
$13.96
Significant Holders of Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ACRS) as of Q2 2022
119 filings reported holding ACRS - Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share as of Q2 2022.
Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ACRS) has 109 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 63.2M shares
of 108M outstanding shares and own 58.34% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (4.9M shares), BlackRock Inc. (4.67M shares), VR Adviser, LLC (4.56M shares), RA CAPITAL MANAGEMENT, L.P. (4.4M shares), BVF INC/IL (3.98M shares), Rock Springs Capital Management LP (3.93M shares), VANGUARD GROUP INC (2.81M shares), Foresite Capital Management IV, LLC (2.81M shares), COMMODORE CAPITAL LP (2.41M shares), and ORBIMED ADVISORS LLC (2.33M shares).
This table shows the top 109 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.